Top

Clinical Reviews in Allergy & Immunology

Published in:

01-12-2011

A Modular View of Cytokine Networks in Atopic Dermatitis

Authors: Irit Carmi-Levy, Bernhard Homey, Vassili Soumelis

Published in: Clinical Reviews in Allergy & Immunology | Issue 3/2011

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease known for its complex pathophysiology involving several immune pathways. In the lesion, signals from barrier disruption, allergens, and microbial colonization are integrated and transmitted to diverse immune cell types, which initiate and maintain the disease. Cytokines are critical in the allergic intercellular communication networks. This review focuses on up-to-date knowledge on the role of cytokines in AD, including recently described functions as well as novel cellular sources. We propose three modules defined as the cellular source of groups of cytokines: (1) keratinocytes, (2) innate immune cells, and (3) T cells. This view enables to better position the function of novel cytokine players, such as thymic stromal lymphopoetin, IL-21, IL-25, and IL-33, in linking different modules and ultimately leading to the allergic inflammatory phenotype. Persistent efforts in the detailed characterization of cytokine networks will be fundamental for the understanding of the complex pathogenic mechanisms of the disease and for guiding targeted therapeutic interventions.

Leung DY, Bieber T (2003) Atopic dermatitis. Lancet 361(9352):151–160PubMedCrossRef

Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA (2004) New insights into atopic dermatitis. J Clin Invest 113(5):651–657PubMed

Leung DY (2000) Atopic dermatitis: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 105(5):860–876PubMedCrossRef

Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3(7):673–680PubMed

Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A et al (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202(4):541–549PubMedCrossRef

Zhou B, Comeau MR, De Smedt T, Liggitt HD, Dahl ME, Lewis DB et al (2005) Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat Immunol 6(10):1047–1053PubMedCrossRef

Gao PS, Rafaels NM, Mu D, Hand T, Murray T, Boguniewicz M et al (2010) Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. J Allergy Clin Immunol 125(6):1403–1407PubMedCrossRef

Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S et al (2007) IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 204(8):1837–1847PubMedCrossRef

Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N et al (2005) Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 14(19):2919–2927PubMedCrossRef

10.

Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R (1998) The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 161(9):4866–4874PubMed

11.

Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D et al (1998) Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 187(5):787–794PubMedCrossRef

12.

Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23(5):479–490PubMedCrossRef

13.

Angelova-Fischer I, Fernandez IM, Donnadieu MH, Bulfone-Paus S, Zillikens D, Fischer TW et al (2010) Injury to the stratum corneum induces in vivo expression of human thymic stromal lymphopoietin in the epidermis. J Invest Dermatol 130(10):2505–2507PubMedCrossRef

14.

Miyata M, Hatsushika K, Ando T, Shimokawa N, Ohnuma Y, Katoh R et al (2008) Mast cell regulation of epithelial TSLP expression plays an important role in the development of allergic rhinitis. Eur J Immunol 38(6):1487–1492PubMedCrossRef

15.

Bogiatzi SI, Fernandez I, Bichet JC, Marloie-Provost MA, Volpe E, Sastre X et al (2007) Cutting edge: proinflammatory and Th2 cytokines synergize to induce thymic stromal lymphopoietin production by human skin keratinocytes. J Immunol 178(6):3373–3377PubMed

16.

Allakhverdi Z, Comeau MR, Jessup HK, Delespesse G (2009) Thymic stromal lymphopoietin as a mediator of crosstalk between bronchial smooth muscles and mast cells. J Allergy Clin Immunol 123(4):958–960, e2PubMedCrossRef

17.

Vu AT, Baba T, Chen X, Le TA, Kinoshita H, Xie Y et al (2010) Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 126(5):985–993PubMedCrossRef

18.

Ito T, Wang YH, Duramad O, Hori T, Delespesse GJ, Watanabe N et al (2005) TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 202(9):1213–1223PubMedCrossRef

19.

Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S et al (2007) Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med 204(2):253–258PubMedCrossRef

20.

Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ (2005) A role for TSLP in the development of inflammation in an asthma model. J Exp Med 202(6):829–839PubMedCrossRef

21.

He R, Oyoshi MK, Garibyan L, Kumar L, Ziegler SF, Geha RS (2008) TSLP acts on infiltrating effector T cells to drive allergic skin inflammation. Proc Natl Acad Sci U S A 105(33):11875–11880PubMedCrossRef

22.

Lu N, Wang YH, Arima K, Hanabuchi S, Liu YJ (2009) TSLP and IL-7 use two different mechanisms to regulate human CD4+ T cell homeostasis. J Exp Med 206(10):2111–2119PubMedCrossRef

23.

Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S et al (2001) IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 15(6):985–995PubMedCrossRef

24.

Angkasekwinai P, Park H, Wang YH, Chang SH, Corry DB, Liu YJ et al (2007) Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 204(7):1509–1517PubMedCrossRef

25.

Ikeda K, Nakajima H, Suzuki K, Kagami S, Hirose K, Suto A et al (2003) Mast cells produce interleukin-25 upon Fc epsilon RI-mediated activation. Blood 101(9):3594–3596PubMedCrossRef

26.

Hvid M, Vestergaard C, Kemp K, Christensen GB, Deleuran B, Deleuran M (2010) IL-25 in atopic dermatitis: a possible link between Inflammation and skin barrier dysfunction? J Invest Dermatol 131(1):150–157PubMedCrossRef

27.

Basham TY, Nickoloff BJ, Merigan TC, Morhenn VB (1985) Recombinant gamma interferon differentially regulates class II antigen expression and biosynthesis on cultured normal human keratinocytes. J Interferon Res 5(1):23–32PubMedCrossRef

28.

O’Regan GM, Irvine AD (2010) The role of filaggrin in the atopic diathesis. Clin Exp Allergy 40(7):965–972PubMedCrossRef

29.

Allakhverdi Z, Smith DE, Comeau MR, Delespesse G (2007) Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 179(4):2051–2054PubMed

30.

Mekori YA, Metcalfe DD (2000) Mast cells in innate immunity. Immunol Rev 173:131–140PubMedCrossRef

31.

Navi D, Saegusa J, Liu FT (2007) Mast cells and immunological skin diseases. Clin Rev Allergy Immunol 33(1–2):144–155PubMedCrossRef

32.

Schreibelt G, Tel J, Sliepen KH, Benitez-Ribas D, Figdor CG, Adema GJ et al (2010) Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 59(10):1573–1582PubMedCrossRef

33.

Kang JY, Nan X, Jin MS, Youn SJ, Ryu YH, Mah S et al (2009) Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31(6):873–884PubMedCrossRef

34.

Jin MS, Kim SE, Heo JY, Lee ME, Kim HM, Paik SG et al (2007) Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130(6):1071–1082PubMedCrossRef

35.

Grewe M, Gyufko K, Schopf E, Krutmann J (1994) Lesional expression of interferon-gamma in atopic eczema. Lancet 343(8888):25–26PubMedCrossRef

36.

Johnson-Huang LM, McNutt NS, Krueger JG, Lowes MA (2009) Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 29(3):247–256PubMedCrossRef

37.

Wang B, Feliciani C, Howell BG, Freed I, Cai Q, Watanabe H et al (2002) Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity. J Immunol 168(7):3303–3308PubMed

38.

Gracie JA, Robertson SE, McInnes IB (2003) Interleukin-18. J Leukoc Biol 73(2):213–224PubMedCrossRef

39.

Homey B, Steinhoff M, Ruzicka T, Leung DY (2006) Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 118(1):178–189PubMedCrossRef

40.

Nakanishi K, Tsutsui H, Yoshimoto T (2010) Importance of IL-18-induced super Th1 cells for the development of allergic inflammation. Allergol Int 59(2):137–141PubMedCrossRef

41.

Sugimoto T, Ishikawa Y, Yoshimoto T, Hayashi N, Fujimoto J, Nakanishi K (2004) Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. J Exp Med 199(4):535–545PubMedCrossRef

42.

Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S et al (1999) IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A 96(24):13962–13966PubMedCrossRef

43.

Yoshimoto T, Min B, Sugimoto T, Hayashi N, Ishikawa Y, Sasaki Y et al (2003) Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med 197(8):997–1005PubMedCrossRef

44.

Matsui K, Wirotesangthong M, Nishikawa A (2008) Peptidoglycan from Staphylococcus aureus induces IL-4 production from murine spleen cells via an IL-18-dependent mechanism. Int Arch Allergy Immunol 146(3):262–266PubMedCrossRef

45.

Swain SL, Weinberg AD, English M, Huston G (1990) IL-4 directs the development of Th2-like helper effectors. J Immunol 145(11):3796–3806PubMed

46.

Renauld JC (2001) New insights into the role of cytokines in asthma. J Clin Pathol 54(8):577–589PubMedCrossRef

47.

Hamelmann E, Gelfand EW (2001) IL-5-induced airway eosinophilia—the key to asthma? Immunol Rev 179:182–191PubMedCrossRef

48.

Jin H, Oyoshi MK, Le Y, Bianchi T, Koduru S, Mathias CB et al (2009) IL-21R is essential for epicutaneous sensitization and allergic skin inflammation in humans and mice. J Clin Invest 119(1):47–60PubMed

49.

Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, Collins M et al (2002) Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells. J Exp Med 196(7):969–977PubMedCrossRef

50.

Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448(7152):480–483PubMedCrossRef

51.

Sarra M, Monteleone I, Stolfi C, Fantini MC, Sileri P, Sica G et al (2010) Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 16(8):1332–1339PubMed

52.

Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, Rolph MS et al (2004) T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells. J Immunol 173(1):68–78PubMed

53.

Peluso I, Fantini MC, Fina D, Caruso R, Boirivant M, MacDonald TT et al (2007) IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178(2):732–739PubMed

54.

Costanzo A, Chimenti MS, Botti E, Caruso R, Sarra M, Monteleone G (2010) IL-21 in the pathogenesis and treatment of skin diseases. J Dermatol Sci 60(2):61–66PubMedCrossRef

55.

Konforte D, Simard N, Paige CJ (2009) IL-21: an executor of B cell fate. J Immunol 182(4):1781–1787PubMedCrossRef

56.

Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5(7):752–760PubMedCrossRef

57.

Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L et al (2006) IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117(2):411–417PubMedCrossRef

58.

Bilsborough J, Leung DY, Maurer M, Howell M, Boguniewicz M, Yao L et al (2006) IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol 117(2):418–425PubMedCrossRef

59.

Raap U, Wichmann K, Bruder M, Stander S, Wedi B, Kapp A et al (2008) Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol 122(2):421–423PubMedCrossRef

60.

Cheung PF, Wong CK, Ho AW, Hu S, Chen DP, Lam CW (2010) Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol 22(6):453–467PubMedCrossRef

61.

Antonysamy MA, Fanslow WC, Fu F, Li W, Qian S, Troutt AB et al (1999) Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J Immunol 162(1):577–584PubMed

62.

Milovanovic M, Drozdenko G, Weise C, Babina M, Worm M (2010) Interleukin-17A promotes IgE production in human B cells. J Invest Dermatol 130(11):2621–2628PubMedCrossRef

63.

Toda M, Leung DY, Molet S, Boguniewicz M, Taha R, Christodoulopoulos P et al (2003) Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J Allergy Clin Immunol 111(4):875–881PubMedCrossRef

64.

Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y (2008) Possible pathogenic role of Th17 cells for atopic dermatitis. J Invest Dermatol 128(11):2625–2630PubMedCrossRef

65.

Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, Zaba LC, Cardinale I, Nograles KE et al (2008) Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 181(10):7420–7427PubMed

66.

Lee FE, Georas SN, Beck LA (2010) IL-17: important for host defense, autoimmunity, and allergy? J Invest Dermatol 130(11):2540–2542PubMedCrossRef

67.

Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A (2003) IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger. J Immunol 170(4):2106–2112PubMed

68.

Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R et al (2006) Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 25(2):309–318PubMedCrossRef

69.

Cua DJ, Tato CM (2010) Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 10(7):479–489PubMedCrossRef

70.

Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J et al (2010) Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 184(7):3336–3340PubMedCrossRef

71.

Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W et al (2010) A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. J Exp Med 207(11):2479–2491PubMedCrossRef

Title: A Modular View of Cytokine Networks in Atopic Dermatitis
Authors: Irit Carmi-Levy
Bernhard Homey
Vassili Soumelis
Publication date: 01-12-2011
Publisher: Humana Press Inc
Published in: Clinical Reviews in Allergy & Immunology / Issue 3/2011
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-010-8239-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Innate Immunity in Atopic Dermatitis

Atopic Dermatitis and the Nervous System

Erratum to: Role of Dendritic Cells in Atopic Dermatitis: An Update

Therapeutic Implications of a Barrier-Based Pathogenesis of Atopic Dermatitis

IgE, Mast Cells, and Eosinophils in Atopic Dermatitis

Role of Dendritic Cells in Atopic Dermatitis: An Update

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials